LivaNova PLC

LivaNova reported record second-quarter revenue and earnings per share and raised its full-year 2026 outlook. Revenue rose 9.8% on a constant currency basis to $391 million, with Cardiopulmonary revenue up 10% to $222 million and Epilepsy revenue up 10%. The company now expects full-year revenue growth of 8% to 9%, up from 7% to 8%, and adjusted diluted earnings per share of $4.30 to $4.40, up from prior guidance. LivaNova also announced a long-term supply agreement with Thermo Fisher Scientific for a critical oxygenator component and said it expects to submit a PMA supplement for its next-generation OSA system between the second half of 2026 and the first half of 2027.

LivaNova announced new data from its PolySync substudy showing that its PolySync programming algorithm increased the cumulative apnea-hypopnea index response rate from 65% to 84.5% in patients with moderate-to-severe obstructive sleep apnea treated with proximal hypoglossal nerve stimulation therapy delivered by the aura6000 System. The findings were presented at SLEEP 2026. The PolySync substudy evaluated patients who did not meet responder criteria after one year of individual-contact stimulation in the OSPREY randomized controlled trial, which previously demonstrated a 65% responder rate. The aura6000 System received FDA premarket approval in March. LivaNova is developing a next-generation OSA device with MRI compatibility, remote configuration, and a rechargeable battery with up to 15 years of life, and plans to file a PMA supplement submission in the second half of 2026.